Elimination of established CD19⁺ tumor by adoptive transfer of UCB-derived CD19R⁺ T cells. (A) Longitudinal monitoring of bioluminescence quantification of Daudi tumor-derived ffLuc-activity in 2 groups of NOD/Scid mice (5 mice per group) and ffLuc-derived bioluminescent signals are graphed over time. (I) Group that received no cellular therapy and (II) group that received cellular therapy with CD8⁺ CD19-specific T-cell clone. Background bioluminescence (as measured in parallel from mouse with no tumor, but which did receive d-luciferin) was calculated for each group at each imaging time point. The red lines correspond to the in vivo optical bioluminescence images of tumor from one mouse selected from each group. (Genetically modified Daudi in vitro ffLuc-activity was 55.1 ± 2.2 CPM/cell [mean ± SD] compared to 0.072 ± 0.017 CPM/cell [mean ± SD] for parental unmodified cells.) (B) Movie still (see Video S2) of time lapse BLI of ffLuc⁺ Daudi in 2 NOD/Scid mice starting the day before adoptive immunotherapy. One mouse received adoptive transfer of CD8⁺ CD19-specific UCB-derived T-cell clone (left), and one mouse received no cellular therapy. Color bar displays relative ffLuc activity in units of p/s/cm²/sr.